đź’ŠArdelyx Faces Regulatory Setback, Arcturus Advances in Phase 2, Abbvie Under Pressure | Biotech Sector Insights
REGN, GILD, AMGN, INCY, and BIIB all showing negative returns. Of note is a class-action lawsuit against Biogen Inc., impacting financials and reputation; investors may seek recovery through Levi & Korsinsky until July 22, 2024.
Welcome to the MarketReader Minute.
Below are AI-generated insights on moves in the health care/biotechnology sector, powered by MarketReader technology.
Tuesday, July 2
IBB [+0.4%]
The iShares Biotechnology ETF experienced significant movements in its holdings, with top contributors like REGN, GILD, AMGN, INCY, and BIIB all showing negative returns. Of note is a class-action lawsuit against Biogen Inc., impacting financials and reputation; investors may seek recovery through Levi & Korsinsky until July 22, 2024.